Exelixis Inc (EXEL)

07:44 AM

Revenues, Treatment Pipeline Driving Exelixis Higher - FX Empire

07:44 AM

Jan 21, 2025

What Makes Exelixis (EXEL) an Investment Bet? - Insider Monkey

Jan 21, 2025

Jan 21, 2025

Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 21, 2025

Jan 20, 2025

Exelixis sets 2025 guidance in line with estimates - MSN

Jan 20, 2025

Jan 20, 2025

Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today? - Yahoo Finance

Jan 20, 2025

Jan 18, 2025

EXEL (Exelixis) Long-Term Debt & Capital Lease Obligation : $194 Mil (As of Sep. 2024) - GuruFocus.com

Jan 18, 2025

Jan 17, 2025

Exelixis (NASDAQ:EXEL) Given New $41.00 Price Target at Oppenheimer - MarketBeat

Jan 17, 2025

Jan 17, 2025

FY2024 EPS Estimates for Exelixis Increased by Analyst - MarketBeat

Jan 17, 2025

Jan 17, 2025

Institutional investors control 74% of Exelixis, Inc. (NASDAQ:EXEL) and were rewarded last week after stock increased 5.9% - Simply Wall St

Jan 17, 2025

Jan 17, 2025

Tallon Kerry Patrick Invests $2.62 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Jan 17, 2025

Jan 16, 2025

Exelixis price target raised to $41 from $38 at Oppenheimer - MSN

Jan 16, 2025

Jan 16, 2025

Oppenheimer bullish on Exelixis stock as cabo sales and R&D progress impress - MSN

Jan 16, 2025

Jan 16, 2025

Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip challenges - Investing.com India

Jan 16, 2025

Jan 15, 2025

Exelixis stock hits 52-week high at $36.98 amid robust growth - Investing.com Nigeria

Jan 15, 2025

Jan 15, 2025

Exelixis (NASDAQ:EXEL) Hits New 52-Week High on Analyst Upgrade - MarketBeat

Jan 15, 2025

Jan 15, 2025

15 Analysts Have This To Say About Exelixis - Benzinga

Jan 15, 2025

Jan 15, 2025

Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, JMP Securities Analyst Says - MarketBeat

Jan 15, 2025

Jan 15, 2025

Burney Co. Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Jan 15, 2025

Jan 15, 2025

FY2025 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat

Jan 15, 2025

Jan 15, 2025

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance

Jan 15, 2025

Jan 15, 2025

Exelixis stock hits 52-week high at $36.98 amid robust growth By Investing.com - Investing.com South Africa

Jan 15, 2025

Jan 14, 2025

Exelixis: Truist raises price target citing increased sales potential - Investing.com

Jan 14, 2025

Jan 14, 2025

Long Term Trading Analysis for (EXEL) - Stock Traders Daily

Jan 14, 2025

Jan 14, 2025

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - MSN

Jan 14, 2025

Jan 14, 2025

FY2024 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat

Jan 14, 2025

Jan 14, 2025

Exelixis Provides Preliminary 2024 Results and Outlook for 2025 - MSN

Jan 14, 2025

Jan 14, 2025

Exelixis says no FDA AdCom for Cabometyx label expansion - MSN

Jan 14, 2025

Jan 13, 2025

Exelixis (NASDAQ:EXEL) Price Target Raised to $37.00 at Piper Sandler - MarketBeat

Jan 13, 2025

Jan 13, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Jan 13, 2025

Jan 13, 2025

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - BioSpace

Jan 13, 2025

Jan 12, 2025

Exelixis Reports Strong $1.8B Revenue for 2024, Projects Growth in 2025 with New Cancer Drug Expansion - StockTitan

Jan 12, 2025

Jan 11, 2025

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib - MSN

Jan 11, 2025

Jan 10, 2025

Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Jan 10, 2025

Jan 09, 2025

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza (EXEL) - Seeking Alpha

Jan 09, 2025

Jan 09, 2025

Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Marketscreener.com

Jan 09, 2025

Jan 09, 2025

Exelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at Meeting - Marketscreener.com

Jan 09, 2025

Jan 09, 2025

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX - Business Wire

Jan 09, 2025

Jan 07, 2025

Range Financial Group LLC Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Jan 07, 2025

Jan 07, 2025

Exelixis (NASDAQ:EXEL) Given New $42.00 Price Target at Guggenheim - MarketBeat

Jan 07, 2025

Jan 06, 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth? - MSN

Jan 06, 2025

Jan 06, 2025

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire

Jan 06, 2025

Jan 06, 2025

Exelixis CEO to Present Corporate Strategy at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025

Jan 05, 2025

Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Jan 05, 2025

Jan 04, 2025

How the (EXEL) price action is used to our Advantage - Stock Traders Daily

Jan 04, 2025

Jan 02, 2025

JPMorgan Chase & Co. Trims Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Jan 02, 2025

Dec 31, 2024

Exelixis price target raised to $38 from $34 at RBC Capital - Yahoo Finance

Dec 31, 2024